Analysis of data from the PROVALID study suggests that endotrophin may act as an early marker of worsening kidney disease in patients with type 2 diabetes.
Research findings presented at the 61st Congress of the European Society of Nephrology by Alexandra Louise Møller, MSc, PhD, of Nordic Biosciences A/S, suggest that patients with type 2 diabetes and elevated endotrophin levels are around 70% more likely to experience a poor renal outcome than those without elevated endotrophin levels.1
PROVALID is a prospective, multinational, non-interventional cohort study that collected information on medical history, physical status, laboratory values, and medication use from more than 4,000 people with type 2 diabetes in five European countries, with the aim of providing clinicians with a database for validating biomarkers. Using data collected in the study, researchers designed the current analysis to evaluate the association between endotrophin levels and the primary endpoint – a composite renal endpoint defined as a sustained 40% decline in eGFR, eGFR <60 ml/min/173 m2, a sustained 30% increase in albuminuria (including transition in albuminuric stage), or renal failure or insufficiency with replacement therapy.1,2
From the PROVALID study, the researchers obtained information from a cohort of 3226 individuals who had baseline plasma endotrophin concentrations. The cohort had a mean age of 64 years (range, 58-70 years), 57% were men, a mean eGFR of 79 (SD, 24) mL/min/1.73 m2, and a mean follow-up period of 3.9 years.1
The analysis showed that elevated endotrophin levels were associated with an increased risk of developing a primary endpoint event (HR, 1.63; P = .0012). After adjusting for age, diabetes duration, HbA1c, atherosclerotic cardiovascular disease, blood pressure, BMI, lipid profile, and eGFR, this increased risk remained (HR, 1.55; P = .012). Subgroup analysis of patients with eGFR >90 mL/min/1.73m2 suggested that elevated endotrophin levels were associated with an increased risk of the primary outcome event (P = .03).1
To learn more about the study and its findings, check out our interview with Møller from the floor of ERA 24.
Møller has no relevant conflicts of interest to share.
References:
- Møller AL, Thöni S, Keller F, et al. #755 Endotrophin as an early marker of renal outcome in patients with type 2 diabetes: findings from the PROVALID study. Nephrology Dialysis Transplantation. Volume 39, Issue Supplement_1. May 2024. https://doi.org/10.1093/ndt/gfae069.528
- Eder S, Leierer J, Kerschbaum J, et al. “Prospective cohort study of patients with type 2 diabetes for biomarker validation (PROVALID) – Study design and baseline characteristics.” Renal blood pressure measurement2018;43(1):181-190. doi:10.1159/000487500
